You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
生物股份(600201.SH):子公司聯合開發藥品取得新獸藥註冊證書
格隆匯 08-17 16:59

格隆匯8月17日丨生物股份(600201.SH)公佈,根據國家《獸藥管理條例》和《獸藥註冊辦法》規定,經農業農村部審查,批准公司全資子公司揚州優邦生物藥品有限公司(“揚州優邦”)、金宇保靈生物藥品有限公司(“金宇保靈”)與兆豐華生物科技(南京)有限公司、雲南生物製藥有限公司、北京科牧豐生物製藥有限公司、兆豐華生物科技(福州)有限公司聯合開發的豬圓環病毒2型、豬肺炎支原體二聯滅活疫苗(重組桿狀病毒DBN01株+DJ-166株)為新獸藥,並核發了《新獸藥註冊證書》。

豬圓環病毒2型、豬肺炎支原體二聯滅活疫苗(重組桿狀病毒DBN01株+DJ-166株)為三類新獸藥,其主要成分為桿狀病毒表達的豬圓環病毒2型Cap蛋白和滅活的豬肺炎支原體蛋白,可同時預防由豬圓環病毒2型感染引起的疾病和豬支原體肺炎。該產品採用的新型水佐劑可以誘導機體迅速產生良好的免疫應答,具有應激反應小、免疫持續期長且免疫效果優良等特點,有效保障豬羣健康。

豬圓環病毒2型、豬肺炎支原體二聯滅活疫苗(重組桿狀病毒DBN01株+DJ-166株)為一針型疫苗,在保證免疫效果的基礎上可以減少豬隻免疫次數和人豬接觸頻率,降低養殖場生物安全風險和勞動成本,從而提升生豬養殖效率。

截至目前,揚州優邦、金宇保靈合計為該疫苗累計投入研發經費3354萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account